Conga Acquires Octiv, Expanding Potential of Both Companies

Xcomony reports that Conga recently acquired Octiv, formerly known as TinderBox. Conga helps to keep businesses efficient by simplifying and automating documents and data. The entire business cycle in Salesforce is supported, streamlined, and automated. However, they are increasingly focused on intelligent document automation. Octiv provides a similar intelligent document service, which is why they initiated a partnership with Conga. According to Octiv CEO David Kerr, Conga will benefit because “Conga will enhance its document automation capabilities by adding the ability to create and manage Web-based documents while measuring engagement throughout the documents’ lifecycles.” 

Intelligent document automation is “software that assists in the creation of electronic documents, often contracts, letters, or other legal correspondence with boilerplate language,” saving companies time in the creation of standard sales, marketing, and legal documents. While the current process is driven by logic and templates, future automation will likely be driven by artificial intelligence. 

So, what makes the current document automation intelligent? Imagine you are drawing up a contract with a company from another country. Intelligent documents automatically adjust prices according to the current exchange values of each country’s currencies. And that’s only the tip of the iceberg. They can accelerate sales processes and help ensure regulatory compliance, protect your brand, and report on any actionable data. These are valuable tasks in our online world. 

More good news is that all of Octiv’s 55 employees will be retained by Conga. Furthermore, Octiv’s 300 customers will be pleased to have access to Conga’s greater resources. Further, Conga intends to expand on the Octiv operation in Indianapolis, and this acquisition’s benefits for Octiv will soon become apparent. And customer benefits in overall satisfaction and product innovation will be revealed too, as synergies between the two companies emerge.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More